Member Info for stevej

Brief details as requested by NewForestLad......... Sareum The company is talking about 2-3 deals with one expected by the year end. The first deal is now due in January and appears from feedback from the AGM in December it’s just a matter of a signature. They have CHK1 in a joint collaboration with ICR and CRT where it is equally shared and from the broker note it could bode very well and be a blockbuster with possible sales of 1 billion if it passes through the clinical trials. Sareum do not believe in being the first to market but “Best In Class” and they have been working on this compound for 5-6 years now and should be transformational for SAR with their share alone. The program that excites me the most is Aurora/FLT3 which is 100% owned and caused the initially spike in Feb 2011 when it released that it had performed with 10 out of 10 success in pre-clinical trials. Sareum have multiple programs CHK1, Aurora, FLT3, VEGFR, TYK2, ALK, Microtubule Binding, FASN, PLK1 and Braf and all 100% owned with the exception of CHK1. They have recently indicated that they need to find more programs from their 100% owned SKIL platform and this is because it is believed that the three deals will tie up co-development, sponsorship and ownership of the majority of the current programs. Couple of links below for your review: http://www.sareum.co.uk/pressreleases.php?newsid=144&year=2011 http://www.sareum.co.uk/pressreleases.php?newsid=162&year=2012 http://www.sareum.co.uk/pressreleases.php?newsid=170&year=2012 http://www.sareum.co.uk/base/images/pdfs/SareumJuly192012.pdf Feel free to ask any questions on the SAR BB……Good luck all

sar ecr clon Good luck all

Yes good progress but losing an asset like John Chivers is a big loss to the business, 36 years of experience and very well respected at all levels........

Sounds like Doc is offering you a get out, which i suggest you take........night all

link to RNS http://www.investegate.co.uk/Article.aspx?id=201107080700090078K